Abstract
Allograft therapies represent a promising form of regenerative treatments. These therapies involve harvesting tissues, particularly amniotic fluid, amniotic membranes, and umbilical cord blood from donors obtained during live delivery. Tissues derived from these sources have demonstrated very low immunogenicity, making them ideal for use in allograft therapies. These tissues undergo minimal processing, such as anticoagulation and cryopreservation, before being delivered to selected patients. Delivery of allograft therapy typically involves injection, which may be performed under imaging guidance. Though these allograft therapies may be considered experimental in a clinical setting, evidence has accumulated of their potential benefits for a diverse range of conditions, including degenerative joint conditions (osteoarthritis, rheumatoid arthritis, joint injury), wound healing, tendinopathy, and various cardiac conditions, nerve conditions, and ophthalmic conditions. The evidence for these indications comes primarily from a variety of in vitro studies, in vivo animal models, as well as human case studies, case series, and nonexperimental studies. Randomized controlled trials are particularly needed to guide the future clinical use of allograft therapies. © Springer Nature Switzerland AG 2023.